StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)
Stock analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a note issued to investors on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a […]
Stock analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a note issued to investors on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a […]